In connection with the start of this new cohort, Arrowhead has earned a USD 25m milestone payment from Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson and Johnson.
AROHBV1001 (NCT03365947) is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses of ARO-HBV in patients with chronic HBV.
Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialise ARO-HBV.
Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a USD 50m milestone payment linked to a Phase 2 study.
Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of USD 25m of the USD 50m Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining USD 25m upon the initiation of a Phase 2 study by Janssen.
Hepatitis B infection is a life-threatening viral infection of the liver, which can cause cirrhosis, scarring of liver tissue, and liver cancer if the infection becomes chronic.
The World Health Organization cites that hepatitis B is a global public health problem with 257m people living with the disease, resulting in 887,000 deaths in 2015.
While a preventive vaccine is available, cure rates for those infected remain low and most patients will endure lifelong therapy.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Using a portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study